WallStreetZenWallStreetZen

How to Buy Pfizer Stock

Pfizer Inc

Pfizer is a general drug manufacturer company located in New York, United States, which is part of the Healthcare sector, and is traded under the ticker PFE on the NYSE exchange.

Pfizer stock last closed at $44.06, down 0.63% from the previous day, and has decreased 17.46% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.3 percentage points. Pfizer stock is currently +6.31% from its 52-week low of $41.45, and -21.77% from its 52-week high of $56.32.

As of Feb 3, 2023, there are 5.61B shares of PFE outstanding. The market cap of PFE is $247.32B. In the last 24 hours, 23.73M PFE shares were traded.

How to Buy Pfizer Stock

Wondering how to invest in Pfizer stock? Here's how.
  1. Figure out where to buy Pfizer stock: You need to decide on an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you figure out where to buy Pfizer stock.
  2. Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
  3. Fund your investment account: Pick your payment method and add your information.
  4. Analyze Pfizer stock: The Pfizer ticker symbol is PFE. Is Pfizer stock a good investment? Should you buy shares of PFE? How do PFE's underlying business fundamentals look? Do top analysts think Pfizer is a good buy? Why has PFE's stock price moved recently? (Hint: Our stock research website can help you understand if PFE is a good stock to buy).
  5. Make your PFE trade: Decide if you will purchase PFE shares at the current market price or use a limit order to purchase PFE shares at a particular price.
  6. Get the latest scoop on your PFE position: Create a watchlist to keep track of your investment in Pfizer stock.

Step 1: Figure out where to buy Pfizer stock

You will need an online brokerage account to access the NYSE market and buy PFE stock.

A brokerage account allows you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

We believe that eToro is the best brokerage. eToro gives you:

  • You can invest in stocks with 0% commissions: Invest without commissions.
  • Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
  • Access to world markets: From Tech to Utilities, New York to Hong Kong — you can fill your portfolio with stocks from the world's leading stock exchanges.
  • Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other financial assets: Such as ETFs and cryptocurrencies.

Get $10 towards your share purchase by signing up for an account with eToro today.

Open eToro Account

Step 2: Create your brokerage account

Now that you've picked your brokerage, you'll need to fill out some personal info so you are able to invest in PFE today.

How to Start a New Brokerage Account on eToro

  1. Click here to get started.
  2. Enter your personal data to start your new brokerage account.
  1. Send your data by clicking the "Create Account" button.
Get started with eToro today

Step 3: Fund your investment account

Now that you have filled out your info on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:

Watch the walkthrough below for more details transferring funds into your new investment account.

Get started with eToro today

Step 4: Analyze Pfizer stock

After you have figured out the best place to buy Pfizer stock, it's very important to research their stock prior to investing, so you truly understand the risk as well as the upside.

Pfizer shares data

PFE Price
$44.06
1w %
0.62%
1y %
-17.46%
5y %
27.08%
P/E
8.3x
P/B
2.67x
P/S
2.48x
PEG
N/A
Revenue
$99.68B
Earnings
$29.77B
Fore. Rev. Growth
-10.46%
Fore. Earn. Growth
-6.76%
Market Cap
$247.32B
Next Earnings
N/A
Next Dividend
Mar 3, 2023

PFE Due Diligence Checks

WallStreetZen was created to help everyday investors do more accurate fundamental analysis.

You can view all of the due diligence checks on PFE's stock page.

What is the fair value of PFE stock?

You can use a variety of different financial metrics, analyses, models, and charts to gauge PFE's intrinsic value.

Using relative valuations metrics:

  • PFE could be undervalued based on its P/E ratio of 8.3x, relative to Drug Manufacturers - General industry P/E ratio of 30.81x
  • PFE may be undervalued based on its P/B ratio of 2.67x, relative to Drug Manufacturers - General industry P/B ratio of 5.14x

You can do more valuation research on PFE's stock here.

A look at PFE Cashflows and Balance Sheet

Passed Health Checks:

  • PFE profit margin has gone up from 28.2% to 29.9% in the past year.
  • PFE earnings of $33.20B is not enough to cover its interest payments.
  • PFE's operating cash flow of $26.60B allows it to safely service it's debt of $36.67B.
  • Total PFE debt is lower than 5 years ago, relative to shareholder equity.
  • There are more short-term assets than long-term liabilities on the PFE balance sheet.
  • There are more short-term assets than short-term liabilities on the PFE balance sheet.

Failed Health Checks:

  • PFE has a relatively high debt to equity ratio of 1.11.

Is it a good time to buy PFE stock, according to Wall Street analysts?

Out of 13 Wall Street analysts who give forecasts on PFE, the consensus analyst rating on Pfizer is a Buy

Please note that analyst ratings are not stock recommendations, nor are they financial advice.

Latest PFE Analyst Upgrades/Downgrades

Terence Flynn, a top 26% analyst from Morgan Stanley maintains PFE with a hold rating and lowers their PFE price target from $53.00 to $45.00, on Feb 1, 2023.

Louise Chen, a bottom 4% analyst from Cantor Fitzgerald reiterates PFE with a strong buy rating and maintains their PFE price target from $75.00 to $75.00, on Feb 1, 2023.

Trung Huynh, a bottom 19% analyst from Credit Suisse maintains PFE with a buy rating and lowers their PFE price target from $54.00 to $50.00, on Feb 1, 2023.

Evan David Seigerman, a top 46% analyst from BMO Capital maintains PFE with a buy rating and lowers their PFE price target from $55.00 to $53.00, on Feb 1, 2023.

Carter Gould, a bottom 8% analyst from Barclays maintains PFE with a hold rating and lowers their PFE price target from $49.00 to $44.00, on Feb 1, 2023.

Gould lowered his price target on Pfizer Inc. by 10.2% following the release of the company's Q4 and FY 2022 earnings report on 2023/01/31.

The analyst reported that he reduced his FY 2023 COVID-related sales estimates post-print.

"The greater risk continues to be to the downside with the end of the public health emergency on the horizon," Gould advised.

He "sees a difficult setup to underwrite rising demand versus current levels," the analyst concluded.

Pfizer reported:

For Q4 2022:

  • EPS of $1.14, which beat the Zacks Consensus Estimate of $1.03 and, by 44.3%, Q4 2021's $0.79.
  • Revenue of $24.29B, which beat the Zacks Consensus Estimate by 0.36%and, by 1.9%, Q4 2021's $23.84B.

For FY 2022:

  • EPS of $$6.58, up 62.1% from FY 2021's $4.06.
  • Revenue of $100.33B, up 13.6% from FY 2021's $88.29B.

For FY 2023, management guided:

  • EPS of $3.25 to $3.45, down Y/Y (51%) to (48%).
  • Revenue of $67B to $71B, down Y/Y (33%) to (29%). ("Company revenues are anticipated to be lower in 2023 than in 2022 due entirely to expected revenue declines for Pfizer’s COVID-19 products."

Pfizer shares have lost 15% of their value YTD against the S&P 500's 4.6% gain.

Chairman & CEO Dr. Albert Bourla commented: "As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time.

"We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond.”

You can dive deeper into what analysts are forecasting on the Pfizer stock forecast page.

PFE Momentum

SMA10
44.17
SMA20
45.34
SMA50
48.78
SMA100
47.1
SMA200
48.58
MACD
-1.47
MACD Signal
-1.48
MACD Histogram
0.01
RSI
31.1
Stochastic %K
32.45
Stochastic %D
29.37
StochRSI %K
73.53
StochRSI %D
63.26

PFE Performance Numbers

Last year, PFE earnings were $29.77B. In the last 5 year, PFE's earnings have gone up by 26.49% per year. This was faster than the Drug Manufacturers - General industry average of 12.86%.

Last year, PFE revenue was $99.68B. In the last five year, PFE's revenue has grown by 13.69% per year. This was faster than the Drug Manufacturers - General industry average of 8.23%.

Find out more about PFE's earnings and revenue performance here.

Are PFE executives and large shareholders buying or selling the stock?

Over the past 12 months, insiders at PFE have bought more shares than they have sold.

Albert Bourla, Chairman CEO of PFE, was the latest PFE insider to buy. They bought $4,017,799.24 worth of PFE shares on Dec 16, 2022.

Dig into more about who owns PFE shares here.

Does PFE provide a stable income stream?

Pfizer pays a dividend of 3.65%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.19%. If you owned $1,000 of PFE stock, you would have received $36.54 in the past 12 months.

Pfizer dividend payments have consistently grown over the past decade and have remained stable.

Get more data about Pfizer dividend yield and history here.

PFE Social Trading Data

One of the primary reasons eToro is our favorite brokerage is because of its social trading community.

Click below to learn what other investors have to say.

Step 5: Make your PFE trade

There are two main types of orders:

  • Market order: A market order is an order to buy or sell a security at the best price on the market.
    Market orders are usually fine for most investors.
  • Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
    If you want to ensure you're buying or selling at a given price, place a limit order.

Click the Open button and your broker will execute the order.

If you need more assistance investing in stocks on eToro, click the how to video below:

Open eToro Account

Step 6: Get the latest scoop on your PFE position

Now that you own some PFE stock, you'll want to keep up with your new investment.

Create a watchlist to keep track of your PFE stock.

PFE Feed

How to Buy Stock in Pfizer

To reiterate, here are the 6 steps to buy Pfizer stock:

  1. Figure out where to buy Pfizer stock
  2. Create your brokerage account
  3. Fund your investment account
  4. Analyze Pfizer stock
  5. Make your PFE trade
  6. Get the latest scoop on your PFE position

If you require a brokerage, eToro is our recommended option.

Get Started with eToro Today

If you would like to get updates on your investment in Pfizer, add PFE to your watchlist by clicking the button below.

NYSE: PFE
$44.06-0.28 (-0.63%)
Updated Feb 3, 2023
Open eToro Account
NYSE: PFE
$44.06-0.28 (-0.63%)
Updated Feb 3, 2023
Open eToro Account

FAQ

How much does it cost to buy one Pfizer share?

As of Feb 3, 2023, it costs $44.06 to buy one share of Pfizer stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.227 shares of PFE.

Get Started with eToro Today

Is now a good time to buy Pfizer stock?

According to 13 Wall Street analysts who monitor Pfizer, their consensus recommendation is to buy Pfizer stock.

What is the best way to buy Pfizer stock?

One way to place an order for Pfizer stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.